The largest bottleneck medical research organisations at the forefront of technology face is access to useful data. These difficulties stem from strict policies that limit access to ML teams instead of allowing technology to enable and ensure responsible data use. Potential ML solutions are greatly stifled due to insufficient ability to access, standardise, and aggregate valuable data that continues to be siloed away. Yet, over the last years we have seen two general paradigms emerge to address important technical challenges.

This course is promoted by Champalimaud Foundation's Fior Lab.

The scientific programme will cover

- Protocols for preparation of human cancer cells for injection;
- Generation of zebrafish xenografts (microinjection in the perivitelline space);
- Metastatic assay;
- Protocols for immunofluorescence;
- Mounting xenografts for confocal imaging;
- Confocal session.

Venue

Champalimaud Center for the Unknown, Lisbon

Dates

06 - 10 May, 2024 - 9:00

Application

Deadline: March 15

“HALLO,” Robin typed on the keyboard.
“HALLO, HOW ARE YOU FEELING?” replied ELIZA, the printed words appearing instantly on the VDU [computer screen]. 
“I’M FEELING TERRIBLE,” Robin replied. 
“WHAT DO YOU MEAN BY THAT PRECISELY?” 
“I’M FEELING DEPRESSED.” 
“WHY DO YOU THINK YOU ARE DEPRESSED?”
“BECAUSE I’M LONELY.” 
“DO YOU LIVE WITH YOUR FAMILY?”
“NO.”
“DO YOU HAVE ANY FRIENDS?” 
“NOT REALLY.” 
“WHY IS THAT?”

Imagine you’re teaching a dog to play fetch. You throw a ball, and your dog sprints after it, picks it up, and runs back. You then reward your panting pup with a treat.

These two programmes provide students with an integrative, state-of-the-art education in either Neuroscience or Cancer. A central goal of these programmes is to foster inquiry and discovery by encouraging active participation, critical thinking, and problem-solving among the students.

“Descending with his brother from the summit of Nanga Parbat, one of the ten highest mountains in the world, [Italian mountaineer] Reinhold Messner felt a third climber ‘descending with us, keeping a regular distance, a little to my right and a few steps away from me, just outside my field of vision’. Messner ‘could not see the figure’ but ‘was certain there was someone there,’ sensing ‘his presence’.

This donation was officially formalised on November 23rd and was announced by Dr. Leonor Beleza, during the latest annual meeting of the Board of Trustees of the Champalimaud Foundation. The announcement took place in the presence of all board members, including Queen Sofia of Spain.

The funding provided by the Würth Group and the non-profit Würth Foundation is intended to support research into pancreatic cancer - a type of malignancy that persists as one of the most lethal, yet remains among the least explored.